Pharmaceutical News

RSS

FDA issues complete response letter regarding the NDA for OMAPRO

ChemGenex Pharmaceuticals announces that the U.S. Food and Drug Administration's Office of Oncology Drug Products has issued a complete response letter regarding the new drug application for OMAPRO for the treatment of adults with chronic myeloid leukemia who have failed prior therapy with imatinib and have the Bcr-Abl T315I mutation.

12 Apr 2010

Resverlogix highlights features of RVX-208 drug at ATVB conference

Resverlogix Corp. announced today that key scientific data was communicated in an oral presentation highlighting the novel features of RVX-208, the Company's lead drug, during the Atherosclerosis, Thrombosis, Vascular Biology conference being held in San Francisco, California.

12 Apr 2010

Cempra to make poster presentations on CEM-101 and CEM-102 at ECCMID 2010

Cempra Pharmaceuticals today announced poster presentations on its novel antibiotic CEM-101, a next-generation macrolide, and CEM-102, the company's proprietary front-loading oral dosing regimen of sodium fusidate, at the 20th European Congress of Clinical Microbiology and Infectious Disease, April 10 to 13, 2010, in Vienna Austria.

12 Apr 2010

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

The antiepileptic drug Vimpat- (lacosamide) (C-V) will be the subject of numerous studies and analyses-both UCB-sponsored and independent-at the 62nd annual American Academy of Neurology meeting, taking place at the Metro Toronto Convention Centre in Toronto from April 10-17.

9 Apr 2010

Gamma-tocotrienol kills prostate tumour cells in animal model studies

Researchers from Davos Life Science in Singapore, in collaboration with scientists at the University of Hong Kong, have shown that gamma-tocotrienol, a member of the vitamin E family, is potent in killing prostate tumour cells in animal model studies. This research was reported this week in the latest edition of Pharmacology.

9 Apr 2010

Penwest Pharmaceuticals signs drug development and commercialization agreement with Alvogen

Penwest Pharmaceuticals Co. today announced that it has signed a drug development and commercialization agreement with Alvogen, Inc. under which Penwest and Alvogen have agreed to identify and select up to five compounds for generic development. Penwest's TIMERx technology may be used for each compound selected.

9 Apr 2010

More public-private partnerships crucial for success of Italian pharmaceutical industry

The newly retired Chief Executive Officer of Roche Pharmaceuticals Bill Burns today led calls for more public-private partnerships in the pharmaceutical industry at the launch of the Italian Institute of Technology's Drug Discovery and Development Unit (D3).

9 Apr 2010

RED BOOK Drug References continue to provide current pricing, product information on drugs

Some vendors have announced they will stop publishing the Average Wholesale Price of drugs in 2011, but Thomson Reuters will continue to supply this needed information in RED BOOK.

9 Apr 2010

Labopharm: Investment report

StockPreacher.com announces an investment report featuring Labopharm Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

9 Apr 2010

Non-psychoactive cannabis to be unveiled at Annual National Clinical Conference on Cannabis Therapeutics

The availability of a new type of medical cannabis strain will be presented for the first time by Steve DeAngelo, who has been featured on CNN, The Wall Street Journal, Fortune Magazine, and The New York Times as Executive Director of one of the nation's top model and non-profit medical cannabis dispensaries, Harborside Health Center in Oakland, California.

9 Apr 2010

Investment report on Somaxon Pharmaceuticals

StockPreacher.com announces an investment report featuring Somaxon Pharmaceuticals, Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

9 Apr 2010

BeaconEquity.com announces investment report featuring Avanir Pharmaceuticals

BeaconEquity.com announces an investment report featuring Avanir Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

9 Apr 2010

Zeria to market, distribute, and sell HemCon's wound and oral care dressings in Japan

HemCon Medical Technologies, Inc., an innovative developer of advanced medical products, is proud to announce the signing of an exclusive licensing agreement with Zeria Pharmaceuticals Co. Ltd., a leading pharmaceutical and consumer healthcare products company. Through this partnership, Zeria will market, distribute, and sell HemCon's line of revolutionary wound and oral care dressings throughout Japan.

9 Apr 2010

Five-year, $3.7M trial evaluates customized warfarin dosage based on patient genetics

A five-year, $3.7 million clinical trial will investigate how to balance the benefits and risks of warfarin, a drug that helps prevent potentially deadly blood clots.

9 Apr 2010

Omega-3 fatty acids improve nerve regeneration, prevent psychotic disorders and reduce cellular aging

Improving nerve regeneration after corneal surgery, preventing psychotic disorders in those at high risk for them and reducing cellular aging are three emerging benefits of the omega-3 fatty acids found in seafood, according to milestone research described in the April 2010 PUFA Newsletter and Fats of Life online publications for health professionals and consumers, respectively.

9 Apr 2010

Wolters Kluwer Health agrees to provide access to Martindale: The Complete Drug Reference

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, has announced an agreement to provide access to Martindale: The Complete Drug Reference as part of premium subscriptions to its flagship drug reference, Facts & Comparisons® eAnswers.

9 Apr 2010

Researchers show iRGD peptide increases treatment efficacy against cancer

Researchers have shown that a peptide (a chain of amino acids) called iRGD helps co-administered drugs penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment efficacy against human breast, prostate and pancreatic cancers in mice, achieving the same therapeutic effect as a normal dose with one-third as much of the drug.

9 Apr 2010

Scientists join USP to foster global harmonization of standards for medicines, food ingredients

To promote international scientific exchange and ultimately foster global harmonization of standards for medicines and food ingredients, scientists from around the world will join the U.S. Pharmacopeial Convention at its headquarters on a rolling basis throughout 2010.

9 Apr 2010

Sanofi-Aventis acquires exclusive global rights to CureDM's Pancreate

CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.

9 Apr 2010

Cell Therapeutics receives FDA Complete Response Letter for Pixuvri NDA

Cell Therapeutics, Inc. today announced that it had received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for Pixuvri™ (pixantrone dimaleate) for relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL").

9 Apr 2010

Pharmaceutical News

FDA issues complete response letter regarding the NDA for OMAPRO

Resverlogix highlights features of RVX-208 drug at ATVB conference

Cempra to make poster presentations on CEM-101 and CEM-102 at ECCMID 2010

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

Gamma-tocotrienol kills prostate tumour cells in animal model studies

Penwest Pharmaceuticals signs drug development and commercialization agreement with Alvogen

More public-private partnerships crucial for success of Italian pharmaceutical industry

RED BOOK Drug References continue to provide current pricing, product information on drugs

Labopharm: Investment report

Non-psychoactive cannabis to be unveiled at Annual National Clinical Conference on Cannabis Therapeutics

Investment report on Somaxon Pharmaceuticals

BeaconEquity.com announces investment report featuring Avanir Pharmaceuticals

Zeria to market, distribute, and sell HemCon's wound and oral care dressings in Japan

Five-year, $3.7M trial evaluates customized warfarin dosage based on patient genetics

Omega-3 fatty acids improve nerve regeneration, prevent psychotic disorders and reduce cellular aging

Wolters Kluwer Health agrees to provide access to Martindale: The Complete Drug Reference

Researchers show iRGD peptide increases treatment efficacy against cancer

Scientists join USP to foster global harmonization of standards for medicines, food ingredients

Sanofi-Aventis acquires exclusive global rights to CureDM's Pancreate

Cell Therapeutics receives FDA Complete Response Letter for Pixuvri NDA

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News